Purple Biotech Ltd.
PPBTNASDAQHealthcareBiotechnology
Latest quote
$1.57
−$0.01 · -0.63%
PPBT company overview
Regular session · ET · Market data may be delayed.
GoAI snapshot
AI-powered factor overview
GoAI score
Sell
Trim exposure — unfavorable risk-reward
Valuation
43
Fair Value
Momentum
17
Strong Down
Sentiment
56
Mixed
Risk resilience
34
High Risk
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
AI-generated, informational only, and not investment advice.
Company profile
Company websitePurple Biotech Ltd., a clinical-stage biotechnology firm based in Rehovot, Israel, is dedicated to pioneering treatments that help cancer patients, particularly in the United States, overcome tumor immune evasion and drug resistance. Its pipeline features two primary oncology assets: CM24: A monoclonal antibody designed to block carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1). This candidate is undergoing Phase 1b/2 clinical trials, where it is being evaluated as a combination therapy with anti-PD-1 checkpoint inhibitors for non-small cell lung cancer and pancreatic cancer. NT219: A small molecule compound that targets insulin receptor substrate 1 and 2 (IRS1/2) as well as signal transducer and activator of transcription (STAT) pathways. NT219 is currently in Phase 1/2 clinical studies for the treatment of recurrent or metastatic solid tumors and squamous cell carcinoma of the head and neck. The company was formerly known as Kitov Pharma Ltd until its rebranding to Purple Biotech Ltd. in December 2020.
- Industry
- Biotechnology
- Sector
- Healthcare
- Headquarters
- IL
- CEO
- Gil Efron
- Listed since
- Nov 20, 2015
- Employees
- 10
Market position
- Volume
- 6.46K
- 0.03× average
- Average volume
- 232.32K
- Average daily volume
- Market cap
- 216.79K USD
- Beta
- -0.54
- Market reference 1
Financials
Financial snapshot
Latest / TTMValuation & yield
- P/E (TTM)
- -0.01×
- P/B (TTM)
- 0.59×
- P/S (TTM)
- 0×
- Dividend yield
- 0.00%
Profitability & efficiency
- Gross margin
- 0.00%
- Operating margin
- 0.00%
- Net margin
- 0.00%
Financial health
- Debt / equity
- 0.01×
- Altman Z-score
- -17.3
- Piotroski F-score
- 3 of 9
Earnings
- Latest fiscal-year EPS
- -11,080
- FY2025
- Latest fiscal-year revenue
- 0 USD
- FY2025
Annual EPS trend
Reported history and fiscal-year consensus
Annual revenue trend
Reported history and fiscal-year consensus
Analyst ratings
Third-party consensus; not a GoAI recommendation.
Recent analyst actions
Corporate actions
Corporate action history
| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | Mar 2, 2026 | 1:10 | — | — |
Stock split | Sep 17, 2024 | 1:20 | — | — |
Stock split | Aug 21, 2020 | 1:10 | — | — |
Effective Mar 2, 2026
1:10
Effective Sep 17, 2024
1:20
Effective Aug 21, 2020
1:10
PPBT peers
Continue in GoAI
Research PPBTresearch.disclaimer